Similarly, FBP1 was proven to inhibit tumor progression in cholangiocarcinoma (CCA) (Zhao et al., 2018), prostate cancer (PCA) (Zhang et al., 2019), and lung adenocarcinoma (LUAD) (Li L. et al., 2020). The gene discussed is FBP1; the disease is posterior cortical atrophy.